RENIN-ANGIOTENSIN SYSTEM (RAS) MODULATORS FOR TREATMENT OF VIRAL INFECTIONS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS OF TREATING USING THE SAME
A method of treating a viral infection may include administering a pharmaceutical composition including a renin-angiotensin system (RAS) modulator to a subject in need thereof to mitigate a cellular and organic impact of the viral infection. The mitigation may include inhibiting reactive oxygen species, inhibiting cytokine release, upregulating angiotensin-converting enzyme 2 (ACE2), and/or downregulating angiotensin II receptor type 1 (AT1). The renin-angiotensin system modulator may include various combinations of an angiotensin receptor blocker (ARB), angiotensin (1-7), an HMG-CoA reductase inhibitor, an angiotensin-converting-enzyme (ACE) inhibitor, 3,3′-diindolylmethane (DIM), indole-3-carbinol (I3C), and/or pirfenidone (PFD). In addition, at least one of the angiotensin receptor blocker, the angiotensin (1-7), the HMG-CoA reductase inhibitor, the angiotensin-converting-enzyme inhibitor, 3,3′-diindolylmethane, indole-3-carbinol, or pirfenidone may be linked to an antioxidant..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 26. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
BROWN MILTON L [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-11-09, Last updated: 2023-11-17 |
|---|
| Patentnummer: |
US2023338348 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018423094 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018423094 | ||
| 003 | DE-627 | ||
| 005 | 20231117101432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231110s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018423094 | ||
| 035 | |a (EPA)US2023338348 | ||
| 035 | |a (EPA)78270228 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a BROWN MILTON L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RENIN-ANGIOTENSIN SYSTEM (RAS) MODULATORS FOR TREATMENT OF VIRAL INFECTIONS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS OF TREATING USING THE SAME |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-11-09, Last updated: 2023-11-17 | ||
| 520 | |a A method of treating a viral infection may include administering a pharmaceutical composition including a renin-angiotensin system (RAS) modulator to a subject in need thereof to mitigate a cellular and organic impact of the viral infection. The mitigation may include inhibiting reactive oxygen species, inhibiting cytokine release, upregulating angiotensin-converting enzyme 2 (ACE2), and/or downregulating angiotensin II receptor type 1 (AT1). The renin-angiotensin system modulator may include various combinations of an angiotensin receptor blocker (ARB), angiotensin (1-7), an HMG-CoA reductase inhibitor, an angiotensin-converting-enzyme (ACE) inhibitor, 3,3′-diindolylmethane (DIM), indole-3-carbinol (I3C), and/or pirfenidone (PFD). In addition, at least one of the angiotensin receptor blocker, the angiotensin (1-7), the HMG-CoA reductase inhibitor, the angiotensin-converting-enzyme inhibitor, 3,3′-diindolylmethane, indole-3-carbinol, or pirfenidone may be linked to an antioxidant. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a HOUCHEN COURTNEY W |4 aut | |
| 700 | 0 | |a KONG YALI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 26. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:26 |g month:10 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78270228/publication/US2023338348A1?q=US2023338348 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 26 |c 10 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 26 |c 10 | ||